Marc Ladanyi - Cancer Science

Author Information

Marc Ladanyi is a distinguished researcher affiliated with the Human Oncology and Pathogenesis Program at the Memorial Sloan Kettering Cancer Center in New York, USA. He also holds a position in the Department of Pathology at the same institution. His work is primarily focused on cancer research, where he has significantly contributed to the understanding and treatment of various cancer types through genomic and molecular pathology.

Research Contributions

Marc Ladanyi has made substantial contributions to cancer research, particularly in understanding the genomic landscape and molecular mechanisms underlying cancer progression and resistance to treatment. His recent publications in 2022 cover a diverse range of topics, including the evolution of RET inhibitor resistance in lung and thyroid cancers, the genomic landscape of endometrial carcinomas, and the characterization of metastatic patterns from clinical sequencing. His work also explores therapeutic targets and resistance mechanisms in cancer, such as the role of MYC in tyrosine kinase inhibitor resistance and the potential of Salt-Inducible Kinase 1 as a therapeutic target in Desmoplastic Small Round Cell Tumor.

Aliases

Marc Ladanyi is known by several aliases, including M. Ladanyi, M Ladanyi, M.. Ladanyi, and Mark Ladanyi. These variations are often used in academic and scientific publications.

Publication and Citation Metrics

Metric	Value
Citation Count	168,295
H-index	179
Paper Count	983

Publications:

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

DOI: 10.1038/s41467-022-28848-x

Year: 2022

Genomic landscape of endometrial carcinomas of no specific molecular profile

DOI: 10.1038/s41379-022-01066-y

Year: 2022

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.

DOI: 10.1016/j.annonc.2022.01.006

Year: 2022

Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool.

DOI: 10.1016/j.prp.2022.153892

Year: 2022

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

DOI: 10.1016/j.cell.2022.01.003

Year: 2022

Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor

DOI: 10.1038/s41389-022-00395-6

Year: 2022

CIC-mediated modulation of MAPK signaling opposes receptor tyrosine kinase inhibitor response in kinase-addicted sarcoma.

DOI: 10.1158/0008-5472.CAN-21-1397

Year: 2022

Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements.

DOI: 10.1158/2159-8290.CD-21-1119

Year: 2022

MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion-positive lung cancer.

DOI: 10.1158/1541-7786.MCR-22-0025

Year: 2022

Clinical utility and performance of an ultra-rapid multiplex RNA-based assay for detection of ALK, ROS1, RET and NTRK1/2/3 rearrangements and MET exon 14 skipping alterations.

DOI: 10.1016/j.jmoldx.2022.03.006

Year: 2022

Can Quitting Tobacco and Alcohol Use Reduce Cancer Risk?

What Are NK1 Receptors?

What are the Limitations of Lasso?

How Are Infections Diagnosed?

What Role Does Next-Generation Sequencing Play?

How Can One Reduce the Risk of Smog-Related Cancer?

What role do support systems play in emotional well-being?

How Do Surgeons Stay Updated with Advances in Cancer Treatment?

What Qualifications are Required?

What are the Side Effects of Tamoxifen and Raloxifene?

Partnered Content Networks

Relevant Topics